Table 5: Association between VDR polymorphisms and the clinicopathological features in HCC subjects.

FokI C>T   Tumor size     Adjusted OR 95% CI Adjusted value   <30 mm % >30 mm %         CC 55 25.00% 57 26.39% 1       CT 108 49.09% 109 50.46% 1.027 0.651 1.62 0.543 TT 57 25.91% 50 23.15% 1.181 0.695 2.008 0.068     Cancer stage               III + IV   I + II           CC 43 18.53% 64 29.91% 1       CT 109 46.98% 99 46.26% 1.639 1.021 2.629 0.054 TT 70 34.48% 51 23.83% 2.335 1.385 3.936 0.001     Liver cirrhosis history               Presence   Absence           CC 40 18.78% 67 30.04% 1       CT 92 43.19% 106 47.53% 1.454 0.899 2.352 0.127 TT 81 38.03% 50 22.42% 2.714 1.602 4.596 <0.001     Lymph node metastasis               Presence   Absence           CC 43 18.45% 64 29.77% 1       CT 96 41.20% 102 47.44% 1.401 0.87 2.256 0.038 TT 77 33.05% 54 25.12% 2.122 1.262 3.57 0.004     Portal invasion               Presence   Absence           CC 53 25.48% 62 27.19% 1       CT 110 52.88% 102 44.74% 1.260 0.843 1.991 0.326 TT 45 21.63% 64 28.07% 0.820 0.482 1.411 0.470     Heavy alcohol intake, (%)               Yes   No           CC 43 28.29% 67 27.02% 1.000       CT 75 49.34% 126 50.81% 0.927 0.575 1.496 0.757 TT 34 22.37% 55 22.18% 0.963 0.543 1.710 0.898